-
EP3612192
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3612192
| EP3612192 - THERAPEUTIC APOPTOTIC CELLS FOR CANCER THERAPY [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 27.06.2024 Database last updated on 18.10.2024 | |
| Former | Grant of patent is intended Status updated on 02.11.2023 | ||
| Former | Examination is in progress Status updated on 15.04.2021 | ||
| Former | Request for examination was made Status updated on 24.01.2020 | ||
| Former | The international publication has been made Status updated on 15.12.2018 | Most recent event Tooltip | 27.06.2024 | Application deemed to be withdrawn | published on 31.07.2024 [2024/31] | Applicant(s) | For all designated states ENLIVEX THERAPEUTICS RDO LTD 14 Einstein Street 7403618 Nes-Ziona / IL | [2023/15] |
| Former [2020/09] | For all designated states Enlivex Therapeutics Ltd. 14 Einstein St. 7403618 Nes-Ziona / IL | Inventor(s) | 01 /
NOVIK, Shai 30 Anni Maamin Street 4721249 Ramat Hasharon / IL | 02 /
MEVORACH, Dror 7 Ma'agal Hanikba Ein-Karem 9574630 Jerusalem / IL | [2020/09] | Representative(s) | Pearl Cohen Zedek Latzer Baratz UK LLP The Gridiron Building One Pancras Square London N1C 4AG / GB | [2020/09] | Application number, filing date | 18812666.8 | 07.06.2018 | [2020/09] | WO2018IL50621 | Priority number, date | US201762516714P | 08.06.2017 Original published format: US 201762516714 P | US201762549465P | 24.08.2017 Original published format: US 201762549465 P | [2020/09] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018225072 | Date: | 13.12.2018 | Language: | EN | [2018/50] | Type: | A1 Application with search report | No.: | EP3612192 | Date: | 26.02.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 13.12.2018 takes the place of the publication of the European patent application. | [2020/09] | Search report(s) | International search report - published on: | IL | 13.12.2018 | (Supplementary) European search report - dispatched on: | EP | 30.04.2020 | Classification | IPC: | A61K35/15, A61K35/17, A61P35/00, C07K16/28, A61K39/00, C07K14/725, C12N5/078, A61K39/395 | [2023/46] | CPC: |
A61P35/00 (EP,KR,US);
A61K35/15 (KR);
A61K2239/31 (EP,US);
A61K2239/38 (EP,US);
A61K2239/48 (EP,US);
A61K35/17 (KR);
A61K38/1774 (US);
A61K39/39533 (EP);
A61K39/3955 (US);
A61K39/39558 (US);
A61K39/4611 (EP,US);
A61K39/4614 (EP,US);
A61K39/4622 (EP,US);
A61K39/4631 (EP,US);
A61K39/464412 (EP,US);
A61K45/06 (KR);
A61K9/0019 (US);
A61P35/02 (US);
C07K14/7051 (EP);
C07K16/2803 (EP);
C07K16/2887 (EP);
C12N5/0634 (EP,KR,US);
C07K2317/622 (EP);
C07K2319/03 (EP);
C07K2319/33 (EP);
C12N2502/1114 (EP);
C12N2502/30 (EP);
| C-Set: |
A61K39/39533, A61K2300/00 (EP)
|
| Former IPC [2020/22] | A61K35/15, A61K35/17, C12N5/078, A61P35/00, A61K39/395, C07K14/00, C07K16/00, C12N5/00 | ||
| Former IPC [2020/09] | A61K35/15, A61K35/17, C12N5/078, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/09] | Title | German: | THERAPEUTISCHE APOPTOSEZELLEN ZUR KREBSTHERAPIE | [2020/09] | English: | THERAPEUTIC APOPTOTIC CELLS FOR CANCER THERAPY | [2020/09] | French: | CELLULES APOPTOTIQUES THÉRAPEUTIQUES DESTINÉES À LA THÉRAPIE DU CANCER | [2020/09] | Entry into regional phase | 20.11.2019 | National basic fee paid | 20.11.2019 | Search fee paid | 20.11.2019 | Designation fee(s) paid | 20.11.2019 | Examination fee paid | Examination procedure | 20.11.2019 | Examination requested [2020/09] | 03.11.2020 | Amendment by applicant (claims and/or description) | 14.04.2021 | Despatch of a communication from the examining division (Time limit: M04) | 12.08.2021 | Reply to a communication from the examining division | 09.12.2021 | Despatch of a communication from the examining division (Time limit: M04) | 05.04.2022 | Reply to a communication from the examining division | 15.11.2022 | Despatch of a communication from the examining division (Time limit: M04) | 14.03.2023 | Reply to a communication from the examining division | 03.11.2023 | Communication of intention to grant the patent | 05.03.2024 | Application deemed to be withdrawn, date of legal effect [2024/31] | 26.03.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2024/31] | Fees paid | Renewal fee | 31.03.2020 | Renewal fee patent year 03 | 14.06.2021 | Renewal fee patent year 04 | 31.03.2022 | Renewal fee patent year 05 | 31.03.2023 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XY]WO2014087408 (ENLIVEX THERAPEUTICS LTD [IL]); | [Y]WO2016132366 (ENLIVEX THERAPEUTICS LTD [IL]); | [X]WO2016170541 (ENLIVEX THERAPEUTICS LTD [IL]); | [PX]US2017360836 (NOVIK SHAI [IL], et al) | by applicant | US4036945 | US4331647 | US4816567 | US4946778 | US5545807 | US5545806 | US5569825 | US5625126 | US5633425 | US5661016 | US6489311 | US2013156794 | WO2014087408 | US2015275175 |